Online Diagnostics business report : Diagnostic center feasibility study in India : India Diagnostic Market study by FINPRO

The total Indian healthcare sector is today 34 billion USD and it is projected to grow to nearly 40 billion by 2012. The diagnostic and pathology market is around two percent of the total market. Indian diagnostic market has been growing fast, at 15-20 percent growth rate but there are lots ofdevelopment needs. The growth rate is estimated to remain the same for the following ten years.

As in all India related issues, again the scale is so amazing - as the Indian interviewees put it: it is all about numbers in India! Also funding is always an issue.

One of the major driving forces is the basic demographic change: the migration to urban cities, with increasing number of people having access to modern healthcare. Consequently, more and more investments are being made in hospitals and clinical laboratories. However, the rural sector is not to be forgotten.- The emerging industry structure is headed towards providing healthcare services as an integrated comprehensive package rather than the traditional concept of providing healthcare infrastructure and reactive medical care. Among the middle and high-income families in India there is a rapidly increasing health consciousness which leads to high demand on preventive health care.

The Indian diagnostic market is clearly divided in two different categories: the non-communicable diseases which are more clearly life-style related, and the communicable diseases which are a big issue in India. Despite the quick economic growth and increasing number of middle class representatives, India is still a developing country with a huge number of rural inhabitants with massive sanitation problems. The basic market requirement is to come up with more indigenous products with affordable prices, bearing in mind that the usability is also in issue: the diagnostic kits should be easy to use, not requiring a doctor.

 

Read complete report : http://www.tekes.fi/en/gateway/PTARGS_0_200_368_859_1841_43/http%3B/tekes-ali1%3B7087/publishedcontent/publish/en_content/campaigns/diagnostics/reports/finpro_feasibility_study_india.pdf

 

 

Online Diagnostics business news : Business Week : Super Religare Buys Piramal Health’s Diagnostics Unit

July 14 (Bloomberg) -- Super Religare Laboratories Ltd., controlled by billionaire brothers Malvinder and Shivinder Singh, agreed to buy Piramal Healthcare Ltd.'s diagnostics unit for 6 billion rupees ($129 million) to become India's largest provider of laboratory services.

The combined entity will have about 170 laboratories serving more than 12 million customers annually, Piramal said in a statement today. Mumbai-based Piramal is also in talks to buy 10 percent of Super Religare and the companies expect to decide on the purchase by tomorrow, Gopal Vaidyanathan, director of strategy at Super Religare, said in a telephone interview today.

The purchase will help increase medical-imaging services including X-rays and ultrasounds at New Delhi-based Super Religare, which has focused on pathology services such as blood tests, Vaidyanathan said. India's diagnostic services market may expand as much as 24 percent annually from 120 billion rupees this year, he said.

"This combination will go a long way in changing the diagnostic services landscape of not just India but also the Asia region," Ajay Piramal, chairman of Piramal group, said in the statement.

Piramal Healthcare fell 1.5 percent to close at 503.85 rupees in Mumbai trading. India's benchmark Sensitive index dropped 0.3 percent.

Read complete news article : http://www.businessweek.com/news/2010-07-14/super-religare-buys-piramal-health-s-diagnostics-unit.html

Online Diagnostics news : Bio Scholar : Kidney function, damage markers could help predict mortality risk

A new study has shown that common tests of kidney function and damage can predict the risk of death from cardiovascular diseases and all causes.

This analysis of 21 studies from 14 countries found that a common blood test to estimate kidney function and a urine test measuring protein (albumin) to estimate kidney damage were strongly related to mortality risk.

"People with high levels of albumin in their urine were at markedly higher risk of mortality than people with low levels of albumin in the urine," said Kunihiro Matsushita, lead author of the study and a postdoctoral fellow with the Johns Hopkins Bloomberg School of Public Health"s Department of Epidemiology.

"The risk of mortality was elevated by nearly 50 percent at 30 mg/g albumin to creatinine ratio, which is the threshold for defining chronic kidney disease. In addition, mortality risk increased more than four-fold at high levels of albuminuria compared to an optimal level of 5 mg/g.

"The data presented in this analysis confirm that the current thresholds are indicative of increased all-cause and cardiovascular mortality risk with both kidney filtration function and urine protein contributing to risk," Matsushita added.

The results are published in the May 17, 2010 issue of the Lancet.

 

Read  original article : http://news.bioscholar.com/2010/05/kidney-function-damage-markers-could-help-predict-mortality-risk.html

Online Diagnostics news : Bio Scholar : Lipid Marker Linked to Worsening of Kidney Disease

In patients with mild to moderate kidney disease, measuring levels of a protein called apolipoprotein A-IV (apoA-IV) can accurately predict the long-term risk of progressive loss of kidney function, reports a study in the February Journal of the American Society of Nephrology.

"Patients with primary kidney disease would like to know whether they are at risk of disease progression, which often results in renal replacement therapy such as hemodialysis and/or kidney transplantation," comments Dr. Florian Kronenberg of Innsbruck Medical University, Austria, one of the study authors. "Our results show that apoA-IV is an excellent predictor for the progression of kidney disease, adding important and additional information besides the exact determination of kidney function."

The seven-year follow-up study included 177 non-diabetic patients with primary kidney disease classified as mild to moderate, based on glomerular filtration rateâ€"a standard measure of kidney function. At the beginning of the study, the patients underwent detailed analysis of blood lipid levelsâ€"not just cholesterol and triglycerides, but also apolipoproteins, which are proteins that carry lipids including cholesterol through the bloodstream.

During the follow-up period, kidney function worsened in approximately 37 percent of patients. Some lipid measurements differed in patients with progressive kidney disease, including a lower level of high-density lipoprotein cholesterol ("good" cholesterol); a higher level of triglycerides; and levels of a specific apolipoprotein, termed apoA-IV.

 

Please read complete story : http://news.bioscholar.com/2006/01/lipid-marker-linked-to-worsening-of-kidney-disease.html

Online Diagnostics news : Bio Scholar : Morning urine test could help doctors save kidneys

A morning urine test is best in detecting declining kidney performance in patients with diabetic kidney disease, according to a new study.

Patients suffering from this disorder often excrete excess protein in the urine, a condition called proteinuria.

Dr. Hiddo Lambers Heerspink, PharmD, (University Medical Center Groningen, in the Netherlands) and his colleagues assessed and compared the ability of various proteinuria measures, including proteinuria versus albuminuria and 24-hours versus early morning sampling, to predict worsening kidney problems.

Albuminuria, a large component of proteinuria, is more specific than total proteinuria and is defined as an excess amount of albumin in the urine.

Amongst the samples – urinary protein from a 24-hour urine collection, urinary albumin from 24-hour and morning sample collection – the team found that measuring the albumin:creatinine ratio in a first morning urine sample was the superior method to predict kidney problems in patients with type 2 diabetes and kidney disease.

The authors noted that standardizing proteinuria measures would improve methods for detecting and monitoring kidney disease.

The study appears in an upcoming issue of the Journal of the American Society Nephrology (JASN).

 

Original article can be read from : http://news.bioscholar.com/2010/07/morning-urine-test-could-help-doctors-save-kidneys.html

Online Business News : Express Healthcare : Indus Health Plus Partners with Thyrocare Technologies

Indus Health Plus, the pioneer in the field of preventive healthcare, has tied up with Thyrocare Technologies Ltd, an ISO 9001-2008 certified pathology lab to provide pathology lab services to its customers- 'Indusites'. Thyrocare has a pan-India presence through a network of 700 service providers.

With this strategic tie up, Indus Health Plus can now provide pathology lab services to its customers more effectively and effortlessly at their door step, just a phone call away. 'Indusites' seeking pathology lab tests can now call the hotline number which would be diverted to the nearest service provider. With this alliance, Indusites can avail a whopping 30 per cent discount on the pathology lab tests.

 

Read complete news : http://www.expresshealthcaremgmt.com/201007/market05.shtml

Online Article : Frost & Sullivan :: Outsourcing in Clinical Diagnostics

 By Alex Wong, Industry Manager, Discovery & Diagnostics 

Outsourcing has been an ongoing practice in the biopharmaceutical, chemical and drug discovery sectors for many years now. Likewise, subcontracting in the field of clinical diagnostics represents no new phenomenon. In a recent Frost & Sullivan end user survey which implicated approximately 500 central labs across Europe, lab managers were asked what they would do if they needed to perform a particular assay for which they did not have the testing capability. Reflective of the current climate of cost-constraints affecting the European diagnostics industry, outsourcing - rather than investing in new technology - emerged as the prominent solution. Following on from last month's insight into outsourcing in the in vitro diagnostics industry, this article highlights some of the key rationale behind the appeal of outsourcing in the clinical laboratory arena. 

More often than not, labs (and companies in general) tend to outsource so as to access capabilities not currently available in-house. Such competencies include:

• accreditations of personnel and lab practices, including quality control and quality assurance processes
• analytical equipment
• experience 
• technical expertise

Employing a contract laboratory / service provider may also aid in:

• combating (skilled) staff shortages
• eliminating purchase of sophisticated, capital-intensive instrumentation
• implementation of 'best practices' - providing an independent viewpoint on current procedures and analytical techniques compared to in-house protocols
• improving result turn around time
• project management - extremely large or low priority assignments realised without neglecting higher priority tasks

 

Read complete article : http://www.frost.com/prod/servlet/market-insight-top.pag?docid=21221081

Online Article : Outsourceportfolio.com : Medical Diagnostics outsourcing to India : Testing waters in diagnostic and lab services outsourcing

In a recent Frost & Sullivan end user survey that implicated 500 central labs across Europe, lab managers were asked what they would do if they needed to perform a particular assay for which they did not have the right testing equipment. Their carefully considered answer, believe it or not, was that they would outsource it to a third-party vendor who had the necessary expertise. Less than a decade ago, they may have answered differently (said they would invest in new technology), but today, in view of the cost-constraining climates that ails the diagnostics industry, outsourcing – rather than investing in new technology – emerges as a more viable solution.

Although savings in excess of 80% per test have been reported in outsourcing lab-testing services to India, a more realistic estimate would be around 25%. The Indian diagnostics and pathology laboratory business is currently estimated around USD 864 million and is growing at a rate of 20 % per annum, according to various surveys.

 

Read compelete article : http://outsourceportfolio.com/testing-waters-diagnostic-lab-services-outsourcing/

 

Online Lab News : Quality India : Laboratory Quality in India: Lab race towards Quality

Pathological laboratories have historically lagged behind in the race towards achieving Quality benchmarks. Not any more. Today, with the help from the Quality Councilof India, laboratories are opting for NABL accreditation.

 

By a rough estimate there are around 100,000 laboratories in the country. The number may seem big but in a country ofour size and population, it is a small percentage.These laboratories are largely in metros and major cities or towns and for those livingin rural and remote regions, a trudge to the nearest town is still a reality.

It is also known that many of these laboratoriesmay not even meet normal and expected Quality standards and many may not even have qualified lab technicians. "If the labs need due recognition then they must register with the Quality Council of India and develop minimum or essential standards. As on date, all over the country, most of the labs do not have a official recognition," opines Dr Venkatesh Thuppil, of National Referral Centre for Lead Poisoning in India, at St John Hospital, Bengaluru.

Popularly known as "Lead Man" for his pioneering work in detecting lead poisoning, Dr Thuppil is critical of the fact that the country lacks a sufficient number of super-speciality laboratories. The medical profession has progressed enormousl while the progress on the laboratory front has remained nearstatic. Dr Thuppil is of the view that "at this juncture we need more super speciality laboratory facilities in the government sector in the diagnosis and prognosis of complicated diseases".

Diagnostic and prognostic pathology investigationsare mostly conducted in good private hospitals, which at any time, are beyond the reach of ordinary citizens who are dependent on government hospitals. But it is unfortunate that even large government hospitals lack skilled technicians to carry out many of the diagnostic and prognostic tests. "I do not share this view. In my hospital I have an elaborate laboratory managed by competent and dedicated doctors and technicians who have acquitted themselves well. There are doctors conducting research here," points out Dr K K Kalra, Medical Superintendent, Chacha Nehru Bal Chikitsalaya (CNBC), the country's foremost paediatric hospital.

CNBC is an exception as Dr A K Agarwal, Dean of Mualana Azad Medical College, points out. "We cannot hide from the fact that, in general, we lack good and Quality pathology laboratories in the country," he says and adds, "it is an important aspect of the medical profession and yet very few opt for laboratory work." Dr Thuppil oncurs and emphasises that "there are not enough competent professionals and technicians to run a laboratory".

 

Read complete article :http://www.qcin.org/nbqp/qualityindia/Vol-2-No3/medicallabspage22.html

Online Business Article : BioTechConnection : Indian Diagnostics business: On The Growth Path-Diagnostics And Pathological Testing Market In India

The Growing Indian Healthcare Industry

The healthcare industry in India is growing at a rapid pace and it is poised to become one of the dominant participants of the Indian economy. According to a Yes Bank and ASSOCHAM report, the Indian health care industry is estimated to grow at 23% p.a. to $77 billion by 2012 from the current $35 billion. The sector has grown at a rate of 9.3% from the year 2000 to 2009.

Of the sum, diagnostic and pathology services would account for $2.5 billion in 2012, more than double its estimated current size of $1billion. The growth in the segment is expected to be driven by consolidation in the industry and increasing insurance penetration among the country's population. Healthcare facilities, inclusive of public and private hospitals, the core sector, around which the healthcare sector is centered, would continue to contribute over 70% of the total sector and touch a figure of $54.7 billion by 2012

According McKinsey report, the Indian healthcare market is expected to grow at a rate of 10-12 percent p.a. This is being driven by a strong local demand and growing population. With average household consumption expected to increase by more than 7 per cent per annum, the annual healthcare expenditure is projected to grow at 10 per cent and also the number of insured is likely to jump from 100 million to 220 million. India's high population makes it an important player in this industry. According to the Insurance Regulatory and Development Authority, the Indian healthcare industry has the potential to show the same exponential growth that the software and pharmaceutical industries have shown in the past decade. Only 10 per cent of the market potential has been tapped till date. This is indicative of the strong growth potential of the Indian healthcare market.

The last few years have seen a rise in the purchasing power of the middle class. With an erratic and sedentary urban lifestyle of the growing middle and upper-middle class in India, healthcare has become an important component of everyone's life. Expenditure on healthcare is rising with increase in self-awareness and availability of high-class healthcare facilities with the advent of private players. According to ICRA 2005 report on Indian Medical Care Industry, India spends 5.10 percent of its GDP on healthcare. India's expenditure on health, in terms of percentage of GDP, is among the highest for developing countries. India is being seen as the preferred destination for quality health solutions due to the major cost advantage over the western countries. 

The burgeoning segment; Pathology and Diagnostics testing market in India

 The diagnostics and pathology testing market in India represents one of the most lucrative markets in the world. The market has grown robustly in past few years on the back of increasing disease prevalence and rising consumer awareness. There are 2 major segments of the Diagnostics Market:

1) Pathological Laboratories             2) Diagnostic kits and reagents

Both of the above segments provide very strong potential for growth, both in the domestic market and as a preferred hub for clinical trials and outsourcing from western countries.

Read complete article : http://biotechconnection.com/?p=1121

Online News : India Today : Rural Health Care : Telemedicine transforms rural health in UP

Hands accustomed to kneading dough are now measuring blood pressure, recording electrocardiograms and becoming acquainted with the Internet.

Kamlesh Gehlot was a housewife in Dhampur village in Bijnor, Uttar Pradesh, before World Health Partners (WHP) convinced her family to invest in a telemedicine centre. Unlike other family businesses where ownership is the preserve of a man, the centres are owned by the woman of the house.

"We always talk about the illiterate population thriving in our villages but forget the rest, which is literate. We picked up women who have been to school, know some English and are keen to come out of their shell. They have done wonderfully after being trained," says Gopi Gopalkrishnan, president, WHP. WHP is a non-profit society focusing on improving access to reproductive healthcare and family planning services in rural and semi rural areas. It launched this 18-month pilot project in 2008 to provide services to 1,000 villages in Meerut, Bijnor and Muzaffarnagar.

The project serves an estimated 3.6 million people, of whom 2 million live in rural areas.

Women like Kamlesh see themselves as well-informed, confident and a critical part of positive change. "I feel happy when women come to me for advice. My daughter, who calls me 'doctor', wants to follow in my footsteps," says Kamlesh.

She has been running the Bhagwanwada SKY Health Centre, about 7 km from her village, for the past nine months.

Husbands also have a role to play though. The men create awareness about family planning among villagers and distribute health products such as non-clinical contraceptives and over-the-counter items.

The telemedicine centre, known as SKY Health Centre, bridges the gap between rural areas and the central medical facility in Delhi, where a team of qualified physicians sit. The centre, which caters to about 10 to 12 villages, is equipped with broadband internet connection, a computer, webcam and a telemedicine gadget called ReMeDi.

 

Read complete News : http://indiatoday.intoday.in/site/Story/80826/India/Telemedicine+transforms+rural+health+in+UP.html

Online Article : Personal experience : Technology Review : Lessons from the Pathology Lab

How lab work in India changed the way I think about science.

By Shaunak Kishore '12

 

Every time I go to India, my grandfather asks me what I want to be. Over the years I've answered astronaut, paleon­tologist, mathematician.

 

Three summers ago, I went to the state of Bihar having just finished my high school's AP bio class. When I arrived at my grandparents' home in Muzaffarpur, I couldn't stop talking about the fantastic experiments we had done. My grandfather, a surgeon, suggested that I look for work in his hospital, and I quickly agreed.

I found a job in the Modern Diagnostic Lab, a pathology lab affiliated with the Sri Krishna Medical College and Hospital. Like any student just starting lab work, I spent most of my time on basic tasks. In the ward, I took blood samples from new patients; if they needed to stay, I sent them to an open bed. For a while I worked in the culture rooms in the back, making bacterial smears and flaming plates using many of the techniques I had practiced that spring in my Pennsylvania high-school lab. This lab's protocols, however, were no longer simply classroom rules. Getting distracted and making mistakes meant wasted resources at best, delayed diagnosis at worst. Although this thought initially scared me and slowed.

Read complete story :http://www.technologyreview.com/article/22453/

Online News : Business News :PRWIRE : RFCL, an ICICI Venture Company Announces Acquisition of Godrej Medical Diagnostics, strengthens its position in infectious diseases portfolio with Malaria and TB Point of Care Testing Kits

RFCL Limited, an ICICI Venture company has acquired the business of Godrej Medical Diagnostics along with its people, brands, assets, liabilities and all current principal alliance partnerships including QBC Diagnostics, USA, Asia Gen Corporation, Taiwan and Uritest Medical Electronic Co Ltd, China. Godrej Medical Diagnostics will be merged and operate as an integrated portfolio within Diagnova, the diagnostics and biomedical sciences division of RFCL.

Noida, UP, January 4, 2008 /India PRwire/ -- RFCL Limited, an ICICI Venture company today announced that it has acquired the business division of Godrej Medical Diagnostics along with its people, brands, assets, liabilities and all current principal alliance partnerships including QBC Diagnostics, USA, Asia Gen Corporation, Taiwan and Uritest Medical Electronic Co Ltd, China. All the key alliance partners are upbeat that business will accelerate growth in the hands of a focused Life Sciences & Laboratory Solutions player like RFCL.

The acquired business of Godrej Medical Diagnostics closing in the current financial year at Rs 120 million and depicting a growth projection of 25% for next 3-4 years will be merged and operate as an integrated portfolio within Diagnova, the diagnostics and biomedical sciences division of RFCL.

With the Indian market witnessing a surge in infectious and life-style diseases, this acquisition will help Diagnova address the growing market needs in a much better way with an integrated product and service offering, a consolidated team of over 180 dedicated diagnostic specialists and its presence in almost all major hospitals and pathology labs

Read complete News : http://www.indiaprwire.com/pressrelease/medical/200801046502.htm

Online: Slide share presentation : Business : Medical Diagnostics Business in India

Please find the link for the business presentation on Medical Diagnostics business in India, prepared by Research on India

 

 

http://www.slideshare.net/ResearchOnIndia/medical-diagnostics-india-sample-1677554

Online News : Express HealthCare: Business: 'By 2012, the Indian Medical Devices and Diagnostic Market is Estimated to Reach 139 Billion'

With Arkray Piramal Medical Private Limited, NPIL and Kyoto, Japan based Arkray, Inc entered into a 49:51 JV to market diagnostic products, mainly SMBG (Self Monitoring Blood Glucose System) in the Indian market on December 9, 2007. The blood glucose system market in India is estimated to be more than Rs 1 billion in size and is estimated to be growing around 20 per cent p.a. Arkray, Inc is a market leader in the self-monitoring blood glucose market in Japan with a dominant market share. Its products are also distributed in over 80 countries around the world. Hidehiro Itokawa, Chairman and CFO, Arkay Piramal Medical Private Limited speaks to Sonal Shukla about the company's offerings and expansion plans for India. Excerpts:

What growth potential do you foresee for Arkay in the evolving diagnostic market in India with products like Glucocard 01?

The Indian market has great potential for companies like Arkray and diagnostic products like the Glucocard 01. Glucocard 01 ensures a virtually pain-free testing experience for the diabetic patient. Glucocard 01 uses a unique combination of a Ruthenium-based mediator and thin film, carbon-coated electrodes, which makes the testing strips (all glucometers require disposable testing strips) free from temperature and humidity interference, thus ensuring accurate and precise results. In addition, the new glucometer provides automatic calibration (minimising chances of manual errors) and a temperature compensation mechanism (using an in-built thermistor). As the blood sample required for testing is minimal (0.3 microlitres) for Glucocard 01, this ensures a virtually error-free and pain-free testing experience for the patient.

By 2012, the Indian medical devices and diagnostics market is estimated to reach Rs 139 billion. India is also fast emerging as the diagnostic capital of the world, currently there are about 40.9 million Indians suffering from diabetes. Arkray Inc is a global leader in medical diagnostic products and over the years has developed a very broad array of medical diagnostic analysers, devices and services. As the Indian market matures, Arkray will look at expansion to further tap into the market in India.

Read complete interview : http://www.expresshealthcare.in/200809/market05.shtml

Online News : VCCIRCLE: Business: Is Piramal Healthcare Now Shedding Diagnostics Biz?

Super Religare and Metropolis Labs may be in the race for the pie.

 

The sellout story in the Indian healthcare industry continues. Piramal Healthcare, the flagship company owned by Ajay Piramal, is believed to be looking at selling its loss-making Rs 200-crore diagnostics business.

Only in May, Piramal Healthcare sold its domestic formalations business to NYSE-listed pharma major Abbott Labs for an up-front payment of $2.12 billion, plus $400 million annually for the next four years.

According to investment banking sources, the companies in the race for Piramal's diagnostic business are Malvinder Singh-owned Super Religare Laboratories Limited (formerly SRL Ranbaxy Ltd.) and Metropolis Labs.

Piramal's diagnostics business revenue stands close to Rs 200 crore. On Friday, Piramal Healthcare stock went up 2% or Rs 10.05 to touch at Rs 509.85 at 12.20 pm on BSE. It had touched a monthly high of Rs 516.6 in early trade.

Piramal Diagnostic Services Pvt Ltd (formerly Wellspring), the wholly owned subsidary, registered a revenue of Rs 194 crore from medical testing charges for the year ended March 31, 2010 against Rs 159 crore for previuos year. But it made a loss of Rs 5.32 crore against the previous loss of Rs 3.71 crore. In May, CNBC had reported Piramal's plans to close down diagnostic business due to losses the company has incurred in the last couple of years. It is learnt that the company is valued between Rs 600-700 crore.

In October 2006, Wellspring had acquired the remaining 40% stake in its joint venture with Dr Phadke's Path Labs in Mumbai. The entity, thereafter renamed as Wellspring-Dr Avinash Phadke Pathlab and Diagnostics. Dr Avinash Phadke, fromer promoter of Phadke's labs, is currently the director& chief of pathology services, Piramal Diagnostics.

Piramal Diagnostics is one among India's leading chain of clinical diagnostic centres, with 124 centres in 85 cities, and over 400 collection centres. According to company statement, Piramal Diagnostics performs over 4 million pathology and radiology tests every year.

Read complete story:http://www.vccircle.com/500/news/is-piramal-healthcare-now-shedding-diagnostics-biz

Company Profile : Diagnostic supplier : Suyog Diagnostics : Mumbai: India

Diagnostics Division:

The company is representing world renowned Diagnostics Companies and selling Diagnostics Kits for Coagulation disorders, Viral Markers for HIV, HBV, HCV, HDV, HEV, Biochemistry, Chromatography kits etc.

Life Science Division:

The company is representing world renowned Diagnostics Companies and selling Chemicals, Bio - Chemicals, FISH Probes, Radio Chemicals, Reagents, Cell Bio, Electrophoresis grade, Neuro chemicals, Molecular Biology grade, DNA Extraction kits, PCR Kits, Restriction Enzymes, DNA Ladders & modifying enzymes, Proteomics, Cell Culture reagents, Plant Tissue Culture Grade Biochemicals, Antibodies etc.

Instrumentation Division:

The company is representing world renowned Diagnostics Companies and selling Fully Automated and Semi Automated Coagulation Analysers, Elisa Reader, Elisa Washer, Elisa Processors, DNA Extraction Equipments, ESR Analyzers etc.

Home Healthcare Division:

The company is representing world renowned Diagnostics Companies and selling Blood Pressure Monitors, Nebulisers, Thermometers etc.

ABOUT SUYOG

The spirit of enterprise knows no frontiers as reflected by the growth of Suyog Diagnostics Pvt. Ltd. since its inception in 1996. Suyog s corporate beliefs of always striving on new challenges, mastering new technologies and undertaking new projects, have laid a strong foundation for a solid future. The team behind the success of this organization comprises of dedicated professionals who have been in the field of diagnostics for the last 15 - 20 years.

With a clear vision, existing infrastructure and professional management, Suyog is confident of achieving the target it has set for itself.

Suyog has strategic alliances through world leaders in the field of diagnostics bringing to India the latest technology in medical field. Suyog mainly deals in Human Diagnostics, Healthcare Products and Plant Diagnostics along with the state-of-the-art laboratory equipment.

For more information about the company visit : http://www.suyogdiagnostics.com

Online News : Bio Scholar : New Developments : Now, paper ”dipstick” test to determine blood type

Scientists have developed the first "dipstick" test for instantly determining a person's blood type at a cost of just a few pennies.

Appearing in ACS semi-monthly journal Analytical Chemistry, the study explains the test which involves placing a drop of blood on a specially treated paper strip.

Gil Garnier and colleagues explain that determining a patient's blood type is critical for successful blood transfusions, which save millions of lives each year worldwide. There are four main blood types: A, B, AB, and O. Use of the wrong blood type in a patient can be fatal. Current methods for determining blood type require the use of sophisticated instruments that are not available in many poor parts of the world. An inexpensive portable test could solve that problem.

The scientists describe development of prototype paper test strips impregnated with antibodies to the antigens on red blood cells that determine blood type. In lab tests using blood samples from human volunteers, the scientists showed that a drop of blood placed on the strip caused a color change that indicated blood type. The results were as accurate as conventional blood typing.

"The paper diagnostics manufacturing cost is a few pennies per test and can promote health in developing countries," the report notes.

Online News : Bio Scholar : New Developments : Ultra-high-field MRI can detect multiple sclerosis in early stage

A new study by researchers from Ohio State University in Columbus, and Columbia University in New York has revealed that Ultra-high-field (7T) MRI can detect multiple sclerosis lesions better than MRI.

Ultra-field high MRI can lead to possible earlier diagnosis and treatment.

For the study, the researchers analyzed post-mortem brain slices from a multiple sclerosis patient using both 3T and 7T MRI. 7T MRI made it possible to detect numerous multiple sclerosis lesions that were not detectable at 3T MRI.

 

Read complete article :http://news.bioscholar.com/2007/05/ultra-high-field-mri-can-detect-multiple-sclerosis-in-early-stage.html

Online News : Bio Scholar : New Developments : SpermCheck technology to let men test sperm count from home

Men could soon be able to test their sperm count from the comfort and privacy of their homes, all thanks to a new technology from the University of Virginia.

Just 10 minutes and few drips of semen will offer men with a more accurate and affordable way to test their sperm count.

Called SpermCheck Fertility, the test, received approval from the Food and Drug Administration in May and will be available online in July, and in pharmacies later in the year.

"One of the impediments to male fertility testing is that men are reluctant to go to the doctor or to deal with the whole question of their fertility," ABC News quoted John Herr, inventor of the test and professor of cell biology at the University of Virginia, as saying.

"This test allows the assessment of male fertility to occur in the privacy of the home. It''s another step that hopefully will give men a greater chance to control and understand their reproductive functions," he added.

Though male infertility is an issue in 40 percent of infertile couples, fertility testing is still predominantly focused on women, said Herr.

He claimed that the test could hopefully bring more gender equity to fertility testing.

The test has more than 95 percent accuracy whether sperm concentration is in the normal range, (above 20 million sperm per millileter), subfertile range (between 2 million and 20 million), or if the subject may be infertile (less than 2 million).

Read complete article: http://news.bioscholar.com/2010/06/spermcheck-technology-to-let-men-test-sperm-count-from-home.html

 

 

Online News : Bio Scholar : Off-the-shelf digital camera helps detect cancer cells

An off-the-shelf digital camera has been turned into an inexpensive device that is powerful enough to let doctors easily distinguish cancerous cells from healthy cells simply by viewing the LCD monitor on the back.

Rice University biomedical engineers and researchers from the University of Texas M.D. Anderson Cancer Center created the device.

"Consumer-grade cameras can serve as powerful platforms for diagnostic imaging," Rice's Rebecca Richards-Kortum, the study's lead author, said.

"Based on portability, performance and cost, you could make a case for using them both to lower health care costs in developed countries and to provide services that simply aren't available in resource-poor countries," she stated.

Richards-Kortum's Optical Spectroscopy and Imaging Laboratory specializes in tools for the early detection of cancer and other diseases. Her team has developed fluorescent dyes and targeted nanoparticles that let doctors zero in on the molecular hallmarks of cancer.

In the new study, the team captured images of cells with a small bundle of fiber-optic cables attached to a 400-dollar Olympus E-330 camera.

When imaging tissues, Richards-Kortum's team applied a common fluorescent dye that caused cell nuclei in the samples to glow brightly when lighted with the tip of the fibre-optic bundle.

Read complete article : http://news.bioscholar.com/2010/06/off-the-shelf-digital-camera-helps-detect-cancer-cells.html

Online News : Bio Scholar : New test to detect lyme disease rapidly developed

A more sensitive test for Lyme disease that may offer earlier detection and lower cost has been developed by scientists at the National Institutes of Health.

Lyme disease is a bacterial infection transmitted to animals and humans by deer ticks.

A skin lesion at the site of the bite is one of the first signs of infection followed by potential neurological, cardiac, and rheumatological complications upon entering the bloodstream.

The Centers for Disease Control and Prevention currently recommends a two-step blood test for diagnosing the disease, however, several limitations include low sensitivity during the early stages of infection, significant time and expense, and an inability to distinguish between active and prior infection.

In previous studies, the luciferase immunoprecipitation system (LIPS) test showed promise at detecting a variety of infectious agents including viral and fungal pathogens.

In the latest research, LIPS was evaluated for its ability to detect antibody responses to Borrelia burgdorferi proteins in blood samples taken from a patient group (some healthy and some with Lyme disease) as well as a control group.

The researchers found that diagnostic levels of 98 percent to 100 percent were achieved using LIPS in conjunction with the synthetic protein VOVO.

"These results suggest that screening by the LIPS test with VOVO and other B. burgdorferi antigens offers an efficient quantitative approach for evaluation of the antibody responses in patients with Lyme disease," say the researchers.

 

Read complete article : http://news.bioscholar.com/2010/06/new-test-to-detect-lyme-disease-rapidly-developed.html

 

Online News : Bio Scholar : Diagnostic blood test can successfully identify rare lung disease

A certain blood test can successfully identify lymphangioleiomyomatosis (LAM) in some patients, eliminating the need for surgical lung biopsy to make a diagnosis, say researchers.

LAM is a rare but serious lung disease that affects women, causing shortness of breath and lung collapse, called a pneumothorax.

The disease occurs when an unusual type of cell invades the lungs and causes tissue destruction by creating holes or cysts in the lung. It can be fatal.

Lisa Young, lead author on the study and researcher at the University of Cincinnati (UC) and Cincinnati Children"s Hospital Medical Center, said that these findings will help with diagnosing LAM and may also be helpful in screening for LAM in women with Tuberous Sclerosis Complex (TSC), a genetic disorder that causes tumors to form in many different organs. TSC is a risk factor for the development of LAM.

In this study, the test was used to analyze the amount of a specific protein—vascular endothelial growth factor-D, or VEGF-D—in patients' blood.

VEGF-D promotes the growth of lymphatic vessels and blood vessels and can be involved in the spread of cancer.
Researchers performed VEGF-D testing in 195 women and found that serum VEGF-D levels were significantly greater in women with LAM than in women with other lung diseases or healthy individuals.

 

Read complete article : http://news.bioscholar.com/2010/07/diagnostic-blood-test-can-successfully-identify-rare-lung-disease.html